Cheap Drugs Create Quality Temptations, FDA Official Says
This article was originally published in The Pink Sheet Daily
FDA will focus on enforcing quality standards, but remains aware of its indirect influence on pricing.
You may also be interested in...
House and Senate letters ask why Mylan's autoinjector doesn't have competition, offering a preview of potential debates on renewal of the generic user fee program.
Industry exec asks FDA to help good manufacturers prove to other countries they continue to meet GMPs even if they are not inspected frequently.
The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.